Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab ± MK-2870 after neoadjuvant chemoimmunotherapy and surgery in resectable stage II–IIIB (N2) NSCLC without pCR
jRCT2021240020Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant MK-2870 + pembrolizumab with Adjuvant pembrolizumab alone (2 arms). Primary endpoint: Disease-free survival (DFS) by BICR. Started Jan 2025; status: recruiting.
02
Drugs
pembrolizumabsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240020.